130 related articles for article (PubMed ID: 9416968)
1. EB 1089, a novel vitamin D analog with strong antiproliferative and differentiation-inducing effects on target cells.
Hansen CM; Mäenpää PH
Biochem Pharmacol; 1997 Dec; 54(11):1173-9. PubMed ID: 9416968
[TBL] [Abstract][Full Text] [Related]
2. Seocalcitol (EB 1089): a vitamin D analogue of anti-cancer potential. Background, design, synthesis, pre-clinical and clinical evaluation.
Hansen CM; Hamberg KJ; Binderup E; Binderup L
Curr Pharm Des; 2000 May; 6(7):803-28. PubMed ID: 10828309
[TBL] [Abstract][Full Text] [Related]
3. A novel vitamin D analog with two double bonds in its side chain. A potent inducer of osteoblastic cell differentiation.
Mahonen A; Jääskeläinen T; Mäenpää PH
Biochem Pharmacol; 1996 Apr; 51(7):887-92. PubMed ID: 8651937
[TBL] [Abstract][Full Text] [Related]
4. A novel immunosuppressive 1alpha,25-dihydroxyvitamin D3 analog with reduced hypercalcemic activity.
Zügel U; Steinmeyer A; Giesen C; Asadullah K
J Invest Dermatol; 2002 Dec; 119(6):1434-42. PubMed ID: 12485451
[TBL] [Abstract][Full Text] [Related]
5. ZK 156718, a low calcemic, antiproliferative, and prodifferentiating vitamin D analog.
Gaschott T; Steinmeyer A; Steinhilber D; Stein J
Biochem Biophys Res Commun; 2002 Jan; 290(1):504-9. PubMed ID: 11779200
[TBL] [Abstract][Full Text] [Related]
6. Nonclassical effects of 1alpha,25-dihydroxyvitamin D(3) and its analogs.
Verstuyf A; Verlinden L; Segaert S; Van Etten E; Mathieu C; Bouillon R
Miner Electrolyte Metab; 1999; 25(4-6):345-8. PubMed ID: 10681664
[TBL] [Abstract][Full Text] [Related]
7. 19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells.
Kubota T; Koshizuka K; Koike M; Uskokovic M; Miyoshi I; Koeffler HP
Cancer Res; 1998 Aug; 58(15):3370-5. PubMed ID: 9699668
[TBL] [Abstract][Full Text] [Related]
8. EB 1089, a novel vitamin D analogue, has strong antiproliferative and differentiation inducing effects on cancer cells.
Mathiasen IS; Colston KW; Binderup L
J Steroid Biochem Mol Biol; 1993 Sep; 46(3):365-71. PubMed ID: 9831485
[TBL] [Abstract][Full Text] [Related]
9. Comparative effects of 1,25-dihydroxyvitamin D3 and EB 1089 on mouse renal and intestinal 25-hydroxyvitamin D3-24-hydroxylase.
Roy S; Martel J; Tenenhouse HS
J Bone Miner Res; 1995 Dec; 10(12):1951-9. PubMed ID: 8619376
[TBL] [Abstract][Full Text] [Related]
10. A novel cytostatic form of autophagy in sensitization of non-small cell lung cancer cells to radiation by vitamin D and the vitamin D analog, EB 1089.
Sharma K; Goehe RW; Di X; Hicks MA; Torti SV; Torti FM; Harada H; Gewirtz DA
Autophagy; 2014; 10(12):2346-61. PubMed ID: 25629933
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy.
Díaz GD; Paraskeva C; Thomas MG; Binderup L; Hague A
Cancer Res; 2000 Apr; 60(8):2304-12. PubMed ID: 10786699
[TBL] [Abstract][Full Text] [Related]
12. MART-10, a less calcemic vitamin D analog, is more potent than 1α,25-dihydroxyvitamin D3 in inhibiting the metastatic potential of MCF-7 breast cancer cells in vitro.
Chiang KC; Chen SC; Yeh CN; Pang JH; Shen SC; Hsu JT; Liu YY; Chen LW; Kuo SF; Takano M; Kittaka A; Sun CC; Juang HH; Chen TC
J Steroid Biochem Mol Biol; 2014 Jan; 139():54-60. PubMed ID: 24125734
[TBL] [Abstract][Full Text] [Related]
13. New 19-nor-(20S)-1alpha,25-dihydroxyvitamin D3 analogs strongly stimulate osteoclast formation both in vivo and in vitro.
Sato M; Nakamichi Y; Nakamura M; Sato N; Ninomiya T; Muto A; Nakamura H; Ozawa H; Iwasaki Y; Kobayashi E; Shimizu M; DeLuca HF; Takahashi N; Udagawa N
Bone; 2007 Feb; 40(2):293-304. PubMed ID: 17070129
[TBL] [Abstract][Full Text] [Related]
14. New vitamin D less-calcemic analog affect human bone cell line and cultured vascular smooth muscle cells similar to other less-calcemic analogs.
Somjen D; Kulesza U; Sharon O; Knoll E; Stern N
J Steroid Biochem Mol Biol; 2014 Mar; 140():1-6. PubMed ID: 24269661
[TBL] [Abstract][Full Text] [Related]
15. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
[TBL] [Abstract][Full Text] [Related]
16. The anti-proliferative and differentiation-inducing effects of vitamin D analogs are not determined by the binding affinity for the vitamin D receptor alone.
Hansen CM; Mathiasen IS; Binderup L
J Investig Dermatol Symp Proc; 1996 Apr; 1(1):44-8. PubMed ID: 9627691
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effects of two less-calcemic vitamin D analogs (Paricalcitol and QW-1624F2-2) in squamous cell carcinoma cells.
Alagbala AA; Johnson CS; Trump DL; Posner GH; Foster BA
Oncology; 2006; 70(6):483-92. PubMed ID: 17237623
[TBL] [Abstract][Full Text] [Related]
18. 24- and 26-homo-1,25-dihydroxyvitamin D3 analogs: potencies on in vitro bone resorption differ from those reported for cell differentiation.
Paulson SK; Perlman K; DeLuca HF; Stern PH
J Bone Miner Res; 1990 Feb; 5(2):201-6. PubMed ID: 2316407
[TBL] [Abstract][Full Text] [Related]
19. Differential antitumor effects of vitamin D analogues on colorectal carcinoma in culture.
Wierzbicka JM; Binek A; Ahrends T; Nowacka JD; Szydłowska A; Turczyk Ł; Wąsiewicz T; Wierzbicki PM; Sądej R; Tuckey RC; Slominski AT; Chybicki J; Adrych K; Kmieć Z; Żmijewski MA
Int J Oncol; 2015 Sep; 47(3):1084-96. PubMed ID: 26260259
[TBL] [Abstract][Full Text] [Related]
20. A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia.
Abe J; Nakano T; Nishii Y; Matsumoto T; Ogata E; Ikeda K
Endocrinology; 1991 Aug; 129(2):832-7. PubMed ID: 1855478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
